Monitoring HIV Viral Load in Resource Limited Settings: Still a Matter of Debate?
Open Access
- 6 December 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (12), e47391
- https://doi.org/10.1371/journal.pone.0047391
Abstract
Consequences of lack of viral monitoring in predicting the effects of development of HIV drug resistance mutations during HAART in resource-limited settings (RLS) is still a matter of debate. To assess, among HIV+ patients receiving their first-line HAART, prevalence of virological failure and genotypic resistance mutations pattern in a Médécins Sans Frontières/Ministry of Health programme in Busia District (Kenya). Patients with HAART treatment for ≥12 months were eligible for the study and those with HIV-RNA ≥5000 copies/ml underwent genotypic study. Total HIV-1 RNA from Dried Blood Spots was extracted using Nuclisens method. 926 patients were included. Among 274 (29.6%) patients with detectable viral load, 55 (5.9%) experienced treatment failure (viral load >5.000 copies/ml); 61.8% were female and 10 (18.2%) had clinical failure. Median CD4 cell count was 116 cell/mm3 (IQR: 54–189). Median HIV-RNA was 32,000 copies/ml (IQR: 11000–68000). Eighteen out of 55 (33%) samples could be sequenced on PR and RT genes, with resistance associated mutations (RAMs) in 15 out of 18 samples (83%). Among patients carrying RAMs, 12/15 (81%) harboured RAMs associated to thymidine analogues (TAMs). All of them (100%) showed M184V resistance associated mutation to lamivudine as well as NNRTI's RAMS. Virological failure rate in resource-limited settings are similar to those observed in developed countries. Resistance mutation patterns were concordant with HAART received by failing patients. Long term detectable viral load confers greater probability of developing resistance and as a consequence, making difficult to find out a cost-effective subsequent treatment regimen.This publication has 33 references indexed in Scilit:
- Elevation of viral load by PCR and use of plasma preparation tubes for quantification of human immunodeficiency virus type 1Journal of Microbiological Methods, 2007
- Implementation of an Antiretroviral Access Program for HIV-1-Infected Individuals in Resource-Limited SettingsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Evaluation of Dried Blood Spots for Human Immunodeficiency Virus Type 1 Drug Resistance TestingJournal of Clinical Microbiology, 2007
- Options for a Second-Line Antiretroviral Regimen for HIV Type 1-Infected Patients Whose Initial Regimen of a Fixed-Dose Combination of Stavudine, Lamivudine, and Nevirapine FailsClinical Infectious Diseases, 2007
- Resistance development over 144 weeks in treatment‐naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903*HIV Medicine, 2006
- Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in AfricaAIDS, 2006
- HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell cultureAIDS, 2006
- Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessmentThe Lancet, 2006
- Laboratory Medicine in Africa: A Barrier to Effective Health CareClinical Infectious Diseases, 2006
- Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIVThe New England Journal of Medicine, 2006